FDA set to make decision on experimental Alzheimer’s drug this week

Published



The Food and Drug Administration is expected to decide by Friday whether to grant accelerated approval for Eisai and Biogen’s experimental Alzheimer’s drug, lecanemab.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.